NewsEvents

Your Yourlocation: Home > Clinical study of tiotropium bromide(136310-93-5) combined with salmeterol /fluticasone in the treatment of chronic obstructive pulmonary disease

Hainan Provincial People's Hospital Wuhai Hong and other studies of tiotropium bromide(136310-93-5) combined with salmeterol /fluticasone in the treatment of chronic obstructive pulmonary disease in clinical research, study found that tiotropium combined with salmeterol /fluticasone treatment of severe COPD over the clinical efficacy of single With salmeterol /fluticasone, and did not increase the incidence of adverse reactions. The article published on 2015 06 "Chinese Journal of Clinical Pharmacology".

The aim of this study was to evaluate the efficacy of tiotropium bromide(136310-93-5) in combination with salmeterol /fluticasone in the treatment of patients with severe chronic obstructive pulmonary disease (COPD).

The researchers selected 100 patients with stable COPD patients were randomly divided into the control group and the test group, 50 cases, the control group were given salmeterol /fluticasone, each 50μg /100μg, 2 times a day, the test group in the control group (FEV1), peak expiratory flow velocity (PEF), peak expiratory flow velocity (PEF), peak expiratory flow velocity (PEF), and peak expiratory flow velocity (PEF) were compared between the two groups after treatment with tiotropium bromide(136310-93-5) (18μg, once daily for 12 weeks) (FEV1 /FVC) and the incidence of adverse reactions.

The results showed that the curative effect of FVC, FEV1, PEF, FEV1 /FVC in experimental group was significantly better than that in control group (P <0.05), and the incidence of adverse drug reaction in the test group was not significantly increased (P> 0.05).

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved